Imaging Somatostatin Receptor Activity in Patients with Active Thyroid Eye Disease Using Tc-99m Depreotide

Clinical Nuclear Medicine

Volumn 28, Issue 5, 2003, Pages 439-440

  Doumas, Argyrios S ^a   Krassas, Gerasimos E ^b   Kaltsas, Themistocles ^b   Pontikides, Nikolaos ^b  

^a Hippocrates Nuclear Medicine Center   (Greece)

^b PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

In 111 Octreotide; Somatostatin Receptors; Tc 99m Depreotide; Thyroid Eye Disease

Indexed keywords

DEPREOTIDE TC 99M; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX;

ARTICLE; CASE REPORT; DIAGNOSTIC IMAGING; DRUG COST; DRUG UPTAKE; ENDOCRINE OPHTHALMOPATHY; EYE DISEASE; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; SCINTIGRAPHY; THYROID DISEASE; COMPARATIVE STUDY; EYE; METABOLISM; SCINTISCANNING;

EYE; GRAVES DISEASE; HUMANS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 85047693246     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RLU.0000063699.88044.D1     Document Type: Article

References (10)

1. Shih WJ, Hirschowitz E, Bensadoun E, et al: Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, Neo Tec) planar and SPECT studies. Ann Nucl Med 16:213, 2002.
2. Francesconi LC, Cyr JE, Pearson DA, et al: Preparation and characterization of (99m Tc) depreotide. J Labelled Comp Radiopharm 42(suppl):S158, 1999.
3. Pearson DA, Lister-James J, McBride WJ, et al: Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 39:1361, 1996.
4. Krassas GE, Heufelder AE: Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144:311, 2001.
5. Kahaly G, Diaz M, Hahn K, et al: Indium 111-pentreotide scintigraphy in Grave's ophthalmopathy. J Nucl Med 36:550, 1995.
6. Postema PT, Krenning EP, Wijngaarde R, et al: (111-In DTPAD-Phe 1) octreotide scintigraphy in thyroidal and orbital Grave's disease: a parameter of disease activity? J Clin Enocrinol Metab 79;1845, 1994.
7. Krassas GE, Dumas A, Pontikides N, et al: Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 42:571, 1995.
8. Krassas GE, Doumas A, Kaltsas T, et al: Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 9:47, 1999.
9. Pham HL, Diggles L, Marcus C, et al: Tc-99m P829: human biodistribution and dosimetry [Abstract]. J Nucl Med 37(suppl):230P, 1996.
10. Depreotide trifluoroacetate (NeoSpect). Package insert. Amersham: Nicomed, November, 2000.